The

Laboratory Report Spring 2011

A Publication of the Department of Pathology and Laboratory Medicine

James M. Musser, M.D., Ph.D.

Table of Contents

Dr. Mary Schwartz Receives Lifetime Achievement Award

Dr. Alberto Ayala Receives Koss Medal

Methodist West Houston Pathology Department Opens

San Jacinto Laboratory Obtains New Instruments

Demand Increases at Sugar Land and Willowbrook Laboratories New Diagnostic Test Offerings

Digital Pathology Section Added Record Year for Residency Applications New Fellowship Program Added

Trainee Spotlight

Three Department Faculty Receive Simmons Funding Office of Academic Development Opens

NIH Awards Grant to Dr. Paul Sumby

New Department Chair

O n July 1, 2010, James M. Musser,

M.D., Ph.D. became the new

chair of the Department of Pa-

thology and Laboratory Medicine, suc-

ceeding Michael W. Lieberman, M.D.,

Ph.D. who retired in June after 22 years

as chair.

“I am extremely honored and humbled

to have been given the opportunity to

lead our Department. I applaud Dr.

Lieberman’s relentless efforts on behalf

of our patients, and his unwavering com-

mitment to excellence in all departmental

activities,” said Dr. Musser. “Our Depart-

ment is extremely fortunate to have many

world-class pathologists. We will con-

tinue to meet the many diagnostic chal-

lenges and therapeutic needs of our pa-

tients, medical staff, and community,”

said Musser.

“Dr. Musser is a tremendous asset to

Methodist and we are fortunate to have

his talents, expertise, and leadership,”

said Ron Girotto, president and chief

executive officer of The Methodist Hospi-

tal System. Dr. Musser assumes his lead-

ership role at a time when the national

pathology and health care landscapes are

undergoing a period of change. “The

effects of the Affordable Care Act on

health care and, specifically, the practice

of pathology, remain unclear. With an

outstanding and fast-growing hospital

system and new technology, the depart-

ment will be nimble, embrace change,

and innovatively solve diagnostic prob-

lems,” said Dr. Musser.

“I am especially excited about our

new initiative in digital pathology made

possible by the strong support of The

Methodist Hospital. This new technology

will help us deliver enhanced, state-of-the

-art diagnostic services to all Methodist

System hospitals,” said Dr. Musser.

Musser, a past recipient of the Chugai

Award for Excellence in Mentoring and

Scholarship from the American Society

for Investigative Pathology, also plans

to enhance already strong departmental

education and training programs. Path-

ology is home to the most ACGME-

accredited training programs of any de-

partment at Methodist. A new depart-

mental Grand Rounds was started in

2010. A post-sophomore year-out training

program will be implemented this year to

help attract the highest caliber of trainees.

Additional fellowships are under consid-

eration.

Dr. Musser holds the Fondren En-

dowed Distinguished Chair and is the co-

director and executive vice president of

The Methodist Hospital Research Insti-

tute. He also directs the Center for Mo-

lecular and Translational Human Infec-

tious Diseases Research. Dr. Musser’s

clinical emphasis is diagnostic microbiol-

ogy.

His research focuses on group A

Streptococcus and Mycobacterium tuberculo-

sis with a special emphasis on genome-

wide analyses of host-pathogen molecular

interactions. He is an elected member of

many medical societies, including the

American Society for Investigative Pathol-

ogy and Association of American Physi-

cians. Dr. Musser was recently elected vice

president of the American Society for In-

vestigative Pathology.

For more information on Dr. Musser,

please visit methodisthealth.com/Musser.

2

3

4

5

6

7

The

LABORATORY REPORT

2

Dr. Mary Schwartz Receives Lifetime Achievement Award from CAP

she received the CAP Spotlight Service

Award.

“The hospital and the Department are

very proud of Dr. Schwartz. We con-

gratulate her on receiving this prestigious

award,” said Dr. James Musser, chair of

the Department of Pathology and Labora-

tory Medicine. “Dr. Schwartz is a world-

class pathologist and astoundingly hard

working. Our patients, our physicians

and our department are very fortunate to

have her practice at Methodist.”

While practicing in all areas of surgical

and cytopathology, Dr. Schwartz’s spe-

cific areas of interest include gastrointes-

tinal pathology, breast pathology, and

head and neck pathology. Her research

interests include discovery and validation

of tumor markers in breast and pancre-

atic cancer.

For more information on Dr. Schwartz,

visit methodisthealth.com/Schwartz. For more

information on the College of American

Pathologists, please visit cap.org.

Mary R. Schwartz, M.D.

Dr. Alberto Ayala Receives Koss Medal from ISUP

D r. Alberto Ayala, the elected

deputy chief of Pathology, was

awarded the Leopold Koss

Medal from the International Society of

Urological Pathology (ISUP) at the US-

CAP 2010 meeting in Washington, D.C.

He received the prestigious award for his

career-level achievement in promoting Dr. Ayala’s Koss Medal

bers who have made a broad and positive

impact on the pathology profession

through contributions to one or more

areas of the College over an extended

period of time. Dr. Schwartz was recog-

nized for her contributions as a superb

educator, diagnostic pathologist, and

pathology activist.

“I am deeply honored and over-

whelmed to receive the CAP Lifetime

Achievement Award,” said Dr. Schwartz.

“It has been a special privilege to be able

to participate in activities of the College

and to serve members of our specialty.”

Dr. Schwartz is actively involved in the

mentoring of residents and fellows, as

well as teaching medical students; she is

the director of the surgical pathology

fellowship in the Department.

In addition to publishing regularly, Dr.

Schwartz serves on several editorial

boards and is an associate editor of Ar-

chives of Pathology and Laboratory Medicine.

She has been named one of the Best Doc-

tors in America since 1996, and in 2009,

M ary R. Schwartz, M.D., the

medical director of Anatomic

Pathology, was one of eight

recipients of the prestigious Lifetime

Achievement Award from the College of

American Pathologists (CAP) at an

awards ceremony on September 25, 2010

at the CAP Annual Meeting in Chicago,

IL. CAP presents the award to its mem-

excellence in the field of urological pa-

thology.

“The Koss Medal is an esteemed

award. Dr. Ayala has earned this medal

for an impressive career that spans over

four decades,” said Dr. James Musser,

chair of the Department of Pathology and

Laboratory Medicine. “Dr. Ayala is a tre-

mendous asset to the Department, the

hospital, and the entire pathology com-

munity. His rare level of expertise has

made him invaluable to all of us.”

The Koss Medal is named for Dr. Leo-

pold Koss, a renowned cytopathologist

who is currently professor emeritus in the

Department of Pathology at the Albert

Einstein College of Medicine in New

York, NY.

Dr. Ayala is a surgical pathologist with

subspecialty interest in urologic and bone

cancers. He joined the Department of

Pathology at The Methodist Hospital in

2004 after a 37-year career in the Depart-

ment of Pathology at The University of

Texas M.D. Anderson Cancer Center

where he served as the director of surgi-

cal pathology and deputy chair.

For more information on Dr. Ayala,

please visit methodisthealth.com/Ayala. For

more information on the International

Society of Urological Pathology (ISUP), visit

isuporg.org.

Alberto G. Ayala, M.D.

The

LABORATORY REPORT

3

New Methodist West Houston Hospital Pathology Department Opens

Dr. Thu Ngo in the new Methodist West Houston Hospital laboratory

San Jacinto Laboratory Obtains New Instruments

T he Pathology Laboratory at San

Jacinto Methodist Hospital has

replaced its two chemistry analyz-

ers and acquired a new hemostasis ana-

lyzer to improve efficiency and address

the growth in surgical volumes at the

hospital.

“As our hospital continues to grow, we

must offer additional pathology ser-

vices,” said Joyce Maldonado, M.D., the

medical director of Laboratory Services at

San Jacinto Methodist. “New equipment

with newer technology increases labora-

tory efficiency and decreases test turn-

around times, permitting us to better

serve our patients and our medical staff.”

Dimension Vista® 500 Intelligent

Lab System

The new Dimension Vista 500 System

is used for chemistry and immunoassay

testing. The instrument has the capacity

to process up to 1,000 tests per hour. It

provides high-sensitivity immunoassays

Clinical chemistry supervisor Lucy Willis and Dr. Claudia Molina in front of one of the new Dimen-

sion Vista 500 chemistry analyzers

O n December 17, 2010, the Meth-

odist West Houston Hospital

opened its doors and admitted

its first patients. The laboratory on the 4th

floor of the hospital officially opened that

day under medical director Dr. Thu Ngo.

Operations in the laboratory went

flawlessly on opening day, largely as a

result of the years of planning and

months of training that prepared the fa-

cility and staff. Drs. Musser, David Ber-

nard, and Rose Anton were on site for the

opening and witnessed the inaugural

Pathology and Laboratory Medicine test

result. Test volumes have increased

steadily since opening.

“Getting the new laboratory up and

running was exciting and exhausting,”

said Dr. Ngo. “The experience I gained in

my years of practicing with Dr. Hazel

Awalt at Willowbrook helped me exten-

integrated with rapid turnaround time

using one primary sample.

This new technology will improve

laboratory efficiency by allowing more of

the San Jacinto core laboratory tests to be

performed onsite, resulting in improved

patient care.

TEG® 5000 Thrombelastograph®

Hemostasis Analyzer

The TEG 5000 System provides a com-

prehensive analysis of hemostasis includ-

ing clotting time, clot formation kinetics,

clot strength and clot lysis from one

whole-blood sample. Moreover, it in-

cludes the assessment of the effects of

antiplatelet drugs including aspirin,

clopidogrel, tirofiban and others. The real

-time hemostasis data can be viewed any-

where in the hospital, including the oper-

ating room.

The addition of the TEG 5000 comes as

the hospital opened its new cardiovascu-

lar surgical suite and hybrid operating

sively in this process. I am fortunate to

have a wealth of experience and support

from all departmental pathologists in our

system hospitals that I can call on at any

time.”

The 7,400 square foot laboratory is staffed

with 14 medical technologists and has

state-of-the-art automated instrumenta-

tion that includes two Stago STA Com-

pact hemostasis analyzers, two Radiome-

ter ABL 90 FLEX blood gas analyzers, a

Siemens Advia Centaur CP Immunoas-

say System, an Ortho Clinical Diagnostics

VITROS 5,1 Fusion chemistry system, an

IRIS IQ200 Series Automated Urinalysis

System, a Sysmex XE-5000 and XT2000i

for automated hematology testing, and

an Ortho ProVue antibody test system.

For more information on Methodist West

Houston, visit methodistwesthouston.com.

room. With this new system in place,

physicians are able to stratify the risk of

post-operative bleeding more accurately

and use transfusion algorithms more re-

liably, therefore decreasing transfusion

requirements, reducing costs and obtain-

ing improved patient outcomes.

For more information on San Jacinto

Methodist, visit sanjacintomethodist.com.

The

LABORATORY REPORT

The Methodist Sugar Land laboratory

also implemented several new tests on-

site including P2Y12 and aspirin platelet

function testing in support of inter-

ventional cardiology activities,

creatinine whole blood testing in

support of Radiology patient effi-

ciency and best practices, platelet

mapping in support of cardiovascu-

lar surgery, TSH, free T4 and rapid

HIV-1 and HIV-2 to improve service

standards, A1 subtyping in the Blood

Bank in support of the new trans-

plant evaluation program and fern

testing to support Women’s Services.

To improve outpatient satisfaction

and service, the laboratory opened a sec-

ond phlebotomy station located in Diag-

nostic Imaging (Main Pavilion).

For more information on Methodist

Sugar Land, visit methodisthealth.com/

sugarland. For more information on Meth-

odist Willowbrook, visit methodisthealth.com/

willowbrook.

H ospital growth and expansion

continue to increase demands

on all areas of the laboratories

at Methodist Sugar Land Hospital

and Methodist Willowbrook Hospi-

tal. In May of 2010, a major expan-

sion at Willowbrook was completed

that doubled the size of the hospital.

Hospital admissions have increased

17% and surgeries have increased

21% compared to 2009. Cardiovascu-

lar surgery was initiated in March of

2010, and a small pediatric unit

opened later that year.

Overall laboratory testing volumes

have increased 38%, including new

on-site testing such as the thromboelasto-

graphy with platelet mapping to support

the new cardiovascular and vascular pro-

cedures, platelet function analysis to sup-

port surgical procedures, creatinine

iSTAT to support Radiology patient effi-

ciency and best practices, and HIV-1 and

4

Hospital Growth Increases Demands on Laboratories

at Methodist Sugar Land and Willowbrook

HIV-2 and HBsAg to meet required turn-

around time standards for the Labor and

Delivery unit.

Dr. Hazel Awalt, medical director of Laboratory Ser-vices for Methodist Willowbrook (left), and histology

technician Beth Beck prepare to receive specimens

from the busy operating rooms.

New Diagnostic Test Offerings: illumigene™ C. difficile

contact Dr. James Davis at 713-441-2437

or jrdavis@tmhs.org. For more information

on illumigene molecular diagnostics sys-

tems, please visit meridianbioscience.com/

illumigene.

mits a more rapid diagnostic result for C.

difficile than conventional assays. Because

of improved sensitivity and specificity,

this test has a much lower false-negative

rate and the need for repeat testing has

been greatly reduced.

For more information on the illumi-

gene C. difficile assay at Methodist, please

Electron microscope image of Clostridium difficile bacteria

T he Methodist Hospital System has

implemented the new illumigene

Clostridium difficile molecular as-

say from Meridian Biosciences, Inc. The

assay employs Loop-Mediated Isother-

mal Amplification (LAMP) technology

for a simple, faster, and more cost-

effective testing process. This test per-

The

LABORATORY REPORT

5

T he Department will implement new digital pathology technology into specific

pathology services this year. Digital pathology has the potential to transform

anatomic pathology and assist faster and more accurate diagnoses. The new

Digital Pathology Section is under the direction of Dr. Michael Thrall. This new ini-

tiative will be the subject of an article in the next issue of The Laboratory Report.

For more information on digital pathology at Methodist, please contact Dr. Michael

Thrall at 713-441-4459 or mjthrall@tmhs.org.

Department Adds Digital Pathology Section

Department Adds New Fellowship Program

molecular genetic pathology,” said Dr.

Monzon. “Our exceptional faculty, part-

ner institutions in the Texas Medical Cen-

ter, and unique elective rotations in

emerging fields of molecular pathology

make our program unusually strong.”

Interest in the new fellowship has been

significant, and the fellowship position

has already been filled until 2013.

For more information on the training

programs offered by the Department,

please visit methodisthealth.com/pathology

training.

Record Year for Residency Applications

T he number of applicants for the

Department’s residency training

program reached an all-time high

this year. In addition to an overall in-

crease in application number, there was

also an increase in the geographic diver-

sity of the applicants and the percentage

with previous research experience. “The

growth in the number of students apply-

“Our fellowship is designed for physi-

cians who have completed pathology or

medical genetics training and are inter-

ested in pursuing a career that includes

Dr. Powell in conference with residents

T he Department recently added a

new fellowship program in mo-

lecular genetic pathology under

the direction of Dr. Federico Monzon.

The fellowship has received approval

from the Accreditation Council for

Graduate Medical Education (ACGME)

and its first fellow began training in Sep-

tember, 2010. Rotations with the medical

genetics programs at The University of

Texas Health Science Center at Houston,

M.D. Anderson Cancer Center, and

Baylor College of Medicine are also part

of the program. The program includes

basic molecular training coupled with

research experiences that produce peer-

reviewed publications.

ing for training in our Department is tes-

tament to the commitment of our faculty

and The Methodist Hospital to training

the next generation of pathologists,” said

Dr. Suzanne Powell, director of the pro-

gram.

For more information on the training

programs offered by the Department, visit

methodisthealth.com/pathologytraining.

Dr. Monzon in the Molecular Diagnostics Labora-tory with Dr. Hidehiro Takei

The

LABORATORY REPORT

therapy for the treatment of anaplastic

large-cell lymphoma (ALCL).

Brain Cancer Treatment

Suzanne Powell, M.D., director of

Neuropathology, will collaborate

with Stephen Wong, Ph.D. (TMHRI

Bioinformatics) and Chris Tsz-

Kwong Man, Ph.D. at Texas Chil-

dren’s Hospital to leverage massive

amounts of data on childhood me-

dulloblastoma to characterize the

four known subtypes of the disease

with the potential of developing

novel, more targeted therapies for

them. Other collaborators include

Dr. Rudy Guerra at Rice University, and

Drs. Pamela New and Robert Grossman

at The Methodist Hospital.

For more information about the Vir-

ginia and L.E. Simmons Family Founda-

tion Collaborative Research Fund, visit

collaborativeresearchfund.org.

Trainee Spotlight: Blythe Gorman, M.D.

D r. Blythe Gorman was the recipient of the first Department of

Pathology and Laboratory Medicine Trainee Leadership and In-

novation Award. She received this award for her overall initia-

tive, leadership and commitment to excellence in patient care.

Dr. Gorman was also awarded the first place medal for her platform talk,

“Comparison of Breast Prognostic/Predictive Markers on Cell Blocks Ob-

tained by Various Methods: Cellient, Formalin and Thrombin,” presented

at the January 2011 Texas Society of Pathologists meeting held in San Anto-

nio. Dr. Gorman received her M.D. degree from Louisiana State University

Health Sciences Center in New Orleans in 2005 and completed her resi-

dency in anatomic and clinical pathology at The University of Texas Medi-

cal Branch in Galveston, Texas.

Dr. Dina Mody, medical director of Cytopathology, Dr. Gor-man and Dr. James Musser at the Texas Society of Patholo-

gists Annual Meeting in San Antonio, TX

Three Department Faculty Receive Research Funding

From Simmons Family Foundation

6

T hree faculty members in the De-

partment have received research

funding from the Virginia and

L.E. Simmons Family Foundation

Collaborative Research Fund.

Through a five-year initiative to

discover new ways to diagnose and

treat diseases, the fund supports

collaboration among researchers at

Rice University, Texas Children’s

Hospital and The Methodist Hospi-

tal Research Institute.

Stem Cell Research

Aleksandar Babic, M.D., Ph.D.,

associate medical director of Trans-

fusion Medicine, will lead a team of

investigators to evaluate whether stem

cells can be obtained from human amni-

otic fluid, thus avoiding the limitations of

harvesting them from embryos or other

sources. Dr. Babic will collaborate with

Dr. Malcolm Brenner from the Center for

Cell and Gene Therapy and Drs. Kenneth

Moise and Eric Yvon from Texas Chil-

dren’s Hospital.

Lymphoma Nanotherapy

Youli Zu, M.D., Ph.D., co-director of

Hematopathology, will collaborate with

Michael Wong, Ph.D. at Rice University

to develop a unique nanoparticle-based

Dr. Zu in his laboratory at TMHRI

The

LABORATORY REPORT

Stockbauer, Ph.D., manager of the

OAD. “Let us know how we can

help you and if you have sugges-

tions for additional services we can

provide.”

Philip Randall will be providing

writing and editorial services for

the OAD, and will assist Dr. Stock-

bauer with the development of the

training classes.

For more information about the Of-

fice of Academic Development, call

713-441-5889 or visit our department

website at methodisthealth.com/OAD.

Dr. Paul Sumby Receives NIH Grant for Strep Studies

D r. Paul Sumby, an investigator

in the Department’s Center for

Molecular and Translational

Human Infectious Diseases Research, has

received a five-year R01 grant from the

National Institute of Allergy and Infec-

tious Diseases (NIAID) to study the mo-

lecular mechanisms that determine group

A Streptococcus (GAS) virulence, and

identify new drug targets. GAS causes a

broad spectrum of diseases, including

7

Medicine symposium held on February

18 to commemorate the opening of The

Methodist Hospital Research Institute

building.

For more information on Dr. Sumby

and his laboratory, visit methodisthealth.com/

Sumby.

pharyngitis, rheumatic fever and ne-

crotizing fasciitis, also known as flesh-

eating disease.

Dr. Sumby will use genomic, transcrip-

tomic and proteomic methods to investi-

gate how GAS uses small RNA molecules

to regulate production of virulence-

enhancing proteins, with a view to inhib-

iting this regulation as a novel therapeu-

tic approach. He recently spoke about his

discoveries at the Frontiers in Translational

New Office of Academic Development Opens

Philip Randall

Scientific Writer, OAD

open for business and look forward to

providing services that will help our

department to succeed,” said Kathryn

A new Office of Aca-

demic Development

(OAD) was opened in

January to help our trainees

and faculty increase their schol-

arly contributions. OAD staff

provide manuscript, grant and

poster editing services; assist in

identifying new research fund-

ing opportunities; and present

seminars and training in areas

such as grantsmanship and

scientific writing. The office

and its initial menu of services

arose from a departmental needs

assessment conducted in the fall of 2010.

“Our goal is to help the academic ef-

forts of all faculty and trainees. We are

Kathryn Stockbauer, Ph.D.

Manager, OAD

Dr. Sumby in his laboratory at TMHRI

The

LABORATORY REPORT

Beck D, Ayers S, Wen J, Brandl MB, Pham TD, Webb P, Chang CC, Zhou X. Integrative analysis of next generation sequencing for

small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes. BMC Med Genomics. 2011 Feb 23;4(1):19.

Cagle PT. Pathologists as leaders, innovators, and devoted physicians: special section on pathology in resource-poor nations. Arch

Pathol Lab Med. 2011 Feb;135(2):170.

Cagle PT, Allen TC, Dacic S, Beasley MB, Borczuk AC, Chirieac LR, Laucirica R, Ro JY, Kerr KM.

Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med. 2011 Jan;135(1):110-6. Review.

Cantley RL, Kapur U, Truong L, Cimbaluk D, Barkan GA, Wojcik E, Gattuso P. Fine-needle aspiration diagnosis of metastatic urothe-

lial carcinoma: A review. Diagn Cytopathol. 2011 Jan 6.

Cruz AT, Geltemeyer AM, Starke JR, Flores JA, Graviss EA, Smith KC. Comparing the tuberculin skin test and T-SPOT.TB blood test

in children. Pediatrics. 2011 Jan;127(1):e31-8.

Cuirolo A, Canigia LF, Gardella N, Fernández S, Gutkind G, Rosato A, Mollerach M. Oxacillin- and cefoxitin-susceptible meticillin-

resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2011 Feb;37(2):178-9.

Hu Y, Ma X, Graviss EA, Wang W, Jiang W, Xu B. A major subgroup of Beijing family Mycobacterium tuberculosis is associated with

multidrug resistance and increased transmissibility. Epidemiol Infect. 2011 Jan;139(1):130-8.

Jang SJ, Gardner JM, Ro JY. Diagnostic approach and prognostic factors of cancers. Adv Anat Pathol. 2011 Mar;18(2):165-72.

Jung SY, Jeong J, Shin SH, Kwon Y, Kim EA, Ko KL, Shin KH, Ro J, Lee KS, Park IH, Lee S, Kim SW, Kang HS. Accumulation of p53

determined by immunohistochemistry as a prognostic marker in node negative breast cancer; analysis according to st gallen consen-

sus and intrinsic subtypes. J Surg Oncol. 2011 Mar 1;103(3):207-11.

Kim SA, Lee SR, Huh J, Shen SS, Ro JY. IgG4-associated inflammatory pseudotumor of ureter: clinicopathologic and immunohisto-

chemical study of 3 cases. Hum Pathol. 2011 Feb 18.

King KY, Lew JD, Ha NP, Lin JS, Ma X, Graviss EA, Goodell MA. Polymorphic allele of human IRGM1 is associated with susceptibil-

ity to tuberculosis in African Americans. PLoS One. 2011 Jan 21;6(1):e16317.

Kosarac O, Takei H, Zhai QJ, Schwartz MR, Mody DR. S100P and XIAP expression in pancreatic ductal adenocarcinoma: potential

novel biomarkers as a diagnostic adjunct to fine needle aspiration cytology. Acta Cytol. 2011;55(2):142-8.

Kwon Y, Ro J, Kang HS, Kim SK, Hong EK, Khang SK, Gong G, Ro JY. Clinicopathological parameters and biological markers predict-

ing non-sentinel node metastasis in sentinel node-positive breast cancer patients. Oncol Rep. 2011 Jan 21.

Mody DR, Nayar R, Thrall M. 2001 Bethesda system classification of glandular lesions on cervical cytology. Monogr Clin Cytol.

2011;20:5-14.

Montes M, Sanchez C, Lewis DE, Graviss EA, Seas C, Gotuzzo E, White AC Jr. Normalization of FoxP3(+) regulatory T cells in re-

sponse to effective antiretroviral therapy. J Infect Dis. 2011 Feb 15;203(4):496-9.

Nelson MI, Tan Y, Ghedin E, Wentworth DE, St George K, Edelman L, Beck ET, Fan J, Lam TT, Kumar S, Spiro DJ, Simonsen L, Vi-

boud C, Holmes EC, Henrickson KJ, Musser JM. Phylogeography of the spring and fall waves of the H1N1/09 pandemic influenza

virus in the United States. J Virol. 2011 Jan;85(2):828-34.

Nese N, Martignoni G, Fletcher CD, Gupta R, Pan CC, Kim H, Ro JY, Hwang IS, Sato K, Bonetti F, Pea M, Amin MB, Hes O, Svec A,

Kida M, Vankalakunti M, Berel D, Rogatko A, Gown AM, Amin MB. Pure epithelioid PEComas (so-called epithelioid angiomyoli-

poma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg

Pathol. 2011 Feb;35(2):161-76.

Olsen RJ, Watkins ME, Cantu CC, Beres SB, Musser JM. Virulence of serotype M3 Group A Streptococcus strains in wax worms

(Galleria mellonella larvae). Virulence. 2011 Mar 1;2(2).

Ozcan A, Shen SS, Hamilton C, Anjana K, Coffey D, Krishnan B, Truong LD. PAX 8 expression in non-neoplastic tissues, primary

tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011 Feb 11.

Pflughoeft KJ, Sumby P, Koehler TM. Bacillus anthracis sin locus and regulation of secreted proteases. J Bacteriol. 2011 Feb;193(3):631-9.

Continued page 9

8

RECENT PUBLICATIONS

The

LABORATORY REPORT

Serpa JA, Graviss EA, Kass JS, White AC Jr. Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore). 2011 Jan;90(1):81-6.

Shea PR, Beres SB, Flores AR, Ewbank AL, Gonzalez-Lugo JH, Martagon-Rosado AJ, Martinez-Gutierrez JC, Rehman HA, Serrano-

Gonzalez M, Fittipaldi N, Ayers SD, Webb P, Willey BM, Low DE, Musser JM. Distinct signatures of diversifying selection revealed

by genome analysis of respiratory tract and invasive bacterial populations. Proc Natl Acad Sci USA. 2011 Mar 7. [Epub ahead of print].

Truong LD, Gaber L, Eknoyan G.Obstructive uropathy. Contrib Nephrol. 2011;169:311-26.

Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011 Jan;135(1):92-109. Review.

Wen J, Feng Y, Bjorklund CC, Wang M, Orlowski RZ, Shi ZZ, Liao B, O'Hare J, Zu Y, Schally AV, Chang CC. Luteinizing Hormone-

Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther. 2011 Jan;10

(1):148-58.

Yang Q, Wang H, Cho HY, Jung SJ, Kim KR, Ro JY, Shen SS. Carcinoma of müllerian origin presenting as colorectal cancer: a clinico-

pathologic study of 13 Cases. Ann Diagn Pathol. 2011 Feb;15(1):12-8.

Zhao J, Wang Y, Wang H, Jiang C, Liu Z, Meng X, Song G, Cheng N, Graviss EA, Ma X. Low agreement between the T-SPOT®.TB

assay and the tuberculin skin test among college students in China. Int J Tuberc Lung Dis. 2011 Jan;15(1):134-6.

Zhao N, Bagaria HG, Wong MS, Zu Y. A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large

cell lymphoma. J Nanobiotechnology. 2011 Jan 31;9(1):2.

RECENT PUBLICATIONS continued

9

The Laboratory Report is a publication

of The Methodist Hospital System

Department of Pathology and Labo-

ratory Medicine.

Editor-in-Chief

April A. Ewton, M.D.

Editorial Committee

Hazel L. Awalt, M.D.

Christopher Leveque, M.D.

Claudia P. Molina, M.D.

Seema Mullick, M.D.

Thu Ngo, M.D.

Steven Shen, M.D., Ph.D.

Paul Sumby, Ph.D.

Ping Wang, Ph.D.

Editorial Coordinator

Philip Randall

The Methodist Hospital

Clare Rose, M.B.A.

Manuel Hinojosa, M.H.A.

The Laboratory Report